NCT04624633 2026-02-25Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLDana-Farber Cancer InstitutePhase 2 Active not recruiting29 enrolled 9 charts
NCT04149821 2023-06-15Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyWeill Medical College of Cornell UniversityPhase 2 Terminated1 enrolled 8 charts